Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole December 7, 2022
Pulmocide’s Lead Drug Candidate Opelconazole (PC945) Granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA September 16, 2021
Pulmocide Raises $92 Million in a Series C Financing to Fund Registration Program for PC945 May 27, 2021
J&J-Backed Pulmocide Fills its Lungs with $92M Series C to Fund Phase 3, Ahead of Possible IPO May 27, 2021
A UK Antifungal Player with a Big Pharma Pedigree Bags Fresh Round of Cash as it Races Toward Late-Stage Trial May 27, 2021
Pulmocide announces publication of clinical data in two peer-reviewed publications highlighting potential of PC945, a novel inhaled antifungal drug candidate, in lung infections March 11, 2021
